For technical assistance or to report a suspected adverse drug reaction, contact Merck
Animal Health at 1-800-224-5318.
BRAVECTO kills fleas and prevents flea infestations for 12 weeks. BRAVECTO
Chew and BRAVECTO Topical Solution for Dogs kills ticks (black-legged tick, American dog tick,
and brown dog tick) for 12 weeks and also kills lone star ticks for 8 weeks. BRAVECTO Topical
Solution for Cats kills black-legged ticks for 12 weeks and American dog ticks for 8 weeks.
IMPORTANT SAFETY INFORMATION
BRAVECTO has not been shown to be effective for
12-weeks' duration in puppies or kittens less than 6 months of age. Fluralaner is a member of the
isoxazoline class. This class has been associated with neurologic adverse reactions including tremors,
ataxia, and seizures. BRAVECTO Chew for Dogs: The most commonly reported adverse reactions include
vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. BRAVECTO is not effective
against lone star ticks beyond 8 weeks of dosing. Seizures have been reported in dogs receiving isoxoline
class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures
or neurologic disorders. BRAVECTO Topical Solution for Dogs: The most commonly reported
adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist
dermatitis/rash. Bravecto is not effective against lone star ticks beyond 8 weeks of dosing. For topical use
only. Avoid oral ingestion. Seizures have been reported in dogs receiving isoxoline class drugs, even in
dogs without a history of seizures. Use caution in dogs with a history of seizures or neurologic disorders.
BRAVECTO Topical Solution for Cats: The most commonly reported adverse reactions include
vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO
is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral
ingestion. The safety of BRAVECTO has not been established in breeding, pregnant and lactating cats.
Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats
without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders.
BRAVECTO Plus (fluralaner and moxidectin topical solution) for Cats: The most commonly reported adverse reactions include vomiting, hair loss, itching, diarrhea, lethargy, dry skin, elevated ALT, and hypersalivation. BRAVECTO PLUS has not been shown to be effective for 2 months in kittens less than 6 months of age. For topical use only. Avoid oral ingestion. The safety of BRAVECTO PLUS has not been established in breeding, pregnant and lactating cats. Fluralaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. Use with caution in cats that are heartworm positive. The effectiveness of BRAVECTO PLUS to prevent heartworm disease after bathing or water immersion has not been evaluated.
References:
1. BRAVECTO Chew for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2014.
2. BRAVECTO Topical Solution for Dogs [prescribing information]. Madison, NJ: Merck Animal
Health; 2016.
3. BRAVECTO Topical Solution for Cats [prescribing information]. Madison, NJ: Merck Animal
Health; 2016.
4. Freedom of Information Summary, NADA 141-426. Approved May 15, 2014.
5. Freedom of Information Summary, NADA 141-459. Approved July 20, 2016.
6. Lavan et al. J Vet Sci Technol. 2017;8:439.
7. Dryden et al. Parasites & Vectors. 2015;8:364.
8. Dryden et al. Parasites & Vectors. 2018;11:422.
9. Burgio et al. Parasites & Vectors. 2016;9:626.
10. CAPC website, Guidelines–Ticks. Available at www.capcvet.org/guidelines/ticks/. Updated April 2017.
Accessed December 20, 2018.
11. Walther et al. Parasites & Vectors. 2014;7:86.
12. Walther et al. Parasites & Vectors. 2014;7:481.